

Indication	<p>For the treatment of hormone receptor-positive, HER2 negative, locally advanced or metastatic breast cancer in people who have had previous endocrine therapy only if: The patient either has:</p> <ul style="list-style-type: none"> • progressive disease whilst still receiving adjuvant or neoadjuvant endocrine therapy for early breast cancer with no subsequent endocrine therapy received following disease progression. • progressive disease within 12 or less months of completing adjuvant endocrine therapy for early breast cancer with no subsequent endocrine therapy received following disease progression. • progressive disease on 1st line endocrine therapy for advanced/metastatic breast cancer with no subsequent endocrine therapy received following disease progression. <p>NB The patient should have had no prior treatment with a CDK 4/6 inhibitor unless either abemaciclib (in combination with fulvestrant) or ribociclib (in combination with fulvestrant) has had to be stopped within 6 months of its start solely as a consequence of dose-limiting toxicity and in the clear absence of disease progression or a CDK 4/6 inhibitor has been previously received as adjuvant therapy and treatment was completed without disease progression at least 12 months prior to the first diagnosis of recurrent or metastatic disease.</p>
Treatment Intent	Palliative
Frequency and number of cycles	28 days Until disease progression or excessive toxicity or patient choice to discontinue.
Monitoring Parameters pre-treatment	<ul style="list-style-type: none"> • Monitor FBC, U&Es and LFTs at baseline, day 15 of cycle 1 and at the beginning of each cycle for 6 months and then, if clinically indicated, every 3 months thereafter. • If neuts ≥ 1 and $PLT \geq 100$ proceed with treatment. Otherwise see table 1. • NB: Platelets should be ≥ 50 for intramuscular injection with fulvestrant. • Monitor U&E and LFT at each cycle for 6 months and then every 3 months thereafter. • The most common Grade ≥ 3 adverse reactions of palbociclib were neutropenia, leukopenia, anaemia, fatigue, and infections. • Palbociclib may cause fatigue and patients should exercise caution when driving or using machines. • If patient is pre or peri-menopausal they must have undergone ovarian ablation or suppression with LHRH agonist treatment. • Dose Modifications: • Palbociclib: First dose reduction to 100mg/day, second dose reduction to 75mg/day. If further dose reduction required, discontinue treatment. • Palbociclib: For haematological toxicities see table 1, for non-haematological toxicities see table 2. • Hepatic impairment: No dose adjustment of palbociclib or fulvestrant is required for patients with mild or moderate hepatic impairment (Child-Pugh classes A and B), although use fulvestrant with caution. For patients with severe hepatic impairment (Child-Pugh class C), the recommended dose of palbociclib is 75 mg once daily for 21 consecutive days followed by 7 days off treatment. No data for the use of fulvestrant in severe hepatic impairment.

Protocol No	BRE-073	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	V3	Written by	M.Archer
Supersedes version	V2	Checked by	C.Waters B.Willis V3 updated in line with commissioning criteria change only.
Date	13.02.2025	Authorising consultant (usually NOG Chair)	J.Glendenning

	<ul style="list-style-type: none"> • Renal impairment: No dose adjustment of palbociclib is required for patients with mild, moderate or severe renal impairment (CrCl \geq15 mL/min). Insufficient data are available in patients requiring haemodialysis to provide any dose adjustment recommendation. No dose adjustment of fulvestrant is required for patients with mild or moderate renal impairment (CrCl \geq30 mL/min). Insufficient data are available in patients with severe renal impairment to provide any dose adjustment recommendation, administer with caution. • Interstitial lung disease/pneumonitis Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis (e.g. hypoxia, cough, dyspnoea). In patients who have new or worsening respiratory symptoms and are suspected to have developed ILD/pneumonitis, interrupt palbociclib immediately and evaluate the patient. Permanently discontinue in patients with severe ILD or pneumonitis. NB: Funding arrangements for continuing single agent fulvestrant should be confirmed. • Common drug interactions: (for comprehensive list refer to BNF/SPC) Avoid concomitant use of palbociclib with strong CYP3A inhibitors (e.g. ketoconazole, itraconazole, clarithromycin) and consider an alternative medication with no or minimal CYP3A inhibition. If patients must be co-administered a strong CYP3A inhibitor, reduce palbociclib dose to 75mg/day. If the strong inhibitor is discontinued, increase the palbociclib dose (after 3-5 half-lives of the inhibitor) to the dose used prior to the initiation of the strong CYP3A inhibitor. Concomitant use of palbociclib with strong CYP3A4 inducers (carbamazepine, phenytoin, rifampicin) should be avoided as it may lead to reduced palbociclib exposure. Use with St John’s Wort is contraindicated. Caution with CYP3A substrates with a narrow therapeutic index (e.g. ciclosporine, fentanyl, tacrolimus); the dose of these may need to be reduced as palbociclib may increase their exposure. • For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet and Macmillan information sheet
References	SPC accessed online 19.01.21 BNF accessed online 19.01.2021 CDF list V1.344 accessed online 28.01.2024 KMCC protocol BRE-073 V2

NB For funding information, refer to CDF and NICE Drugs Funding List

Protocol No	BRE-073	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	V3	Written by	M.Archer
Supersedes version	V2	Checked by	C.Waters B.Willis V3 updated in line with commissioning criteria change only.
Date	13.02.2025	Authorising consultant (usually NOG Chair)	J.Glendenning

Table 1: Haematological Toxicities (Table applies to all haematological adverse reactions except Lymphopenia (unless associated with clinical events, e.g., opportunistic infections)).

CTCAE Grade	Dose modifications of palbociclib
If PLT \geq 100 Neuts \geq 1	No dose adjustment is required.
PLT 50-99 Neuts \geq 0.5 Or PLT \geq 100 and Neuts 0.5-0.99	<u>Day 1 and 15 (cycle 1 only)</u> Proceed with fulvestrant, withhold palbociclib and alert consultant. Repeat FBC within 1 week. When recovered to PLT \geq 100 and Neuts \geq 1 restart palbociclib at the <i>same dose</i> . Consider dose reduction in cases of prolonged ($>$ 1 week) recovery from Grade 3 neutropenia or recurrent Grade 3 neutropenia on Day 1 of subsequent cycles.
PLT 25-50	Delay all treatment for 1 week. Repeat FBC in a week and alert consultant.
Grade 3 neutropenia (Neuts 0.5 - $<$ 1.0) + Fever \geq 38.5 °C and/or infection	Withhold palbociclib until recovery to Grade \leq 2*. Resume at next lower dose.
Grade 4 e.g neuts $<$ 0.5 PLT $<$ 25	At any time: Withhold palbociclib until recovery to Grade \leq 2*. Resume at next lower dose.
*Grade \leq 2: neuts \geq 1.0 and PLT \geq 50	

Table 2 Non-haematological toxicities

CTCAE Grade	Dose modifications of palbociclib
Grade 1 or 2	No dose adjustment is required.
Grade \geq 3 non-haematological toxicity (if persisting despite medical treatment)	Withhold until symptoms resolve to: <ul style="list-style-type: none"> • Grade \leq 1; • Grade \leq 2 (if not considered a safety risk for the patient) Resume at the next lower dose.

Protocol No	BRE-073	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	V3	Written by	M.Archer
Supersedes version	V2	Checked by	C.Waters B.Willis V3 updated in line with commissioning criteria change only.
Date	13.02.2025	Authorising consultant (usually NOG Chair)	J.Glendenning

Cycle 1: Cycle length- 28 days

Day	Drug	Dose	Route	Infusion Duration	Administration
Day 1	FULVESTRANT	500mg	intramuscular	Each 5ml (250mg) injection over 1-2 minutes	Administered as 2 x 250mg (5ml) injections, one in each buttock.
Day 15	FULVESTRANT	500mg	intramuscular	Each 5ml (250mg) injection over 1-2 minutes	Administered as 2 x 250mg (5ml) injections, one in each buttock.
TTO	Drug	Dose	Route	Directions	
Day 1	PALBOCICLIB	125mg	PO	Once DAILY for 21 days followed by a 7 day break. Swallow whole, do not chew, crush or split tablets. Take the dose at approximately the same time each day. If a dose is missed or vomiting occurs, an additional dose should not be taken that day. Do not take with grapefruit or grapefruit juice. Available as 125mg, 100mg or 75mg tablets.	
	Metoclopramide	10mg	PO	10mg TDS PRN. Do not take for more than 5 days continuously. Dispense with cycle 1 and then only if required.	

Cycle 2 onwards: repeat every 28 days

Day	Drug	Dose	Route	Infusion Duration	Administration
1	FULVESTRANT	500mg	intramuscular	Each 5ml (250mg) injection over 1-2 minutes	Administered as 2 x 250mg (5ml) injections, one in each buttock.
TTO	Drug	Dose	Route	Directions	
1	PALBOCICLIB	125mg	PO	Once DAILY for 21 days followed by a 7 day break. Swallow whole, do not chew, crush or split tablets. Take the dose at approximately the same time each day. If a dose is missed or vomiting occurs, an additional dose should not be taken that day. Do not take with grapefruit or grapefruit juice. Available as 125mg, 100mg or 75mg tablets.	
	Metoclopramide	10mg	PO	10mg TDS PRN. Do not take for more than 5 days continuously. Only supply if required.	

Protocol No	BRE-073	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.			
Version	V3	Written by		M.Archer	
Supersedes version	V2	Checked by		C.Waters B.Willis V3 updated in line with commissioning criteria change only.	
Date	13.02.2025	Authorising consultant (usually NOG Chair)		J.Glendenning	